Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Unicycive Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Unicycive Therapeutics, Inc.

UNCY

Unicycive Therapeutics, Inc.

About Unicycive Therapeutics, Inc.

Unicycive Therapeutics is a clinical-stage biotech focused on developing innovative kidney disease therapies. Its pipeline includes Oxylanthanum Carbonate, a phosphate binder for hyperphosphatemia, and UNI-494, a potential treatment for acute kidney injury and delayed graft function. The company licenses assets, advances clinical trials, and aims to improve patient adherence and outcomes in renal care markets globally.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Unicycive Therapeutics, Inc.

1
1
Unicycive Therapeutics, Inc. Unicycive Therapeutics Reports $12.8 Million Net Loss and Increased Cash Reserves for Q1 2026

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
Unicycive Therapeutics, Inc. Unicycive Therapeutics Reports $26.6 Million Net Loss and Operational Updates in Annual Filing

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Unicycive Therapeutics, Inc. Unicycive Therapeutics Reports Q3 2025 Financial Results with Increased Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Unicycive Therapeutics, Inc. Unicycive Therapeutics Reports $6.4 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Unicycive Therapeutics, Inc. Unicycive Therapeutics Reports Net Income Turnaround and Strategic Advances in Kidney Disease Treatments

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Unicycive Therapeutics, Inc. Unicycive Therapeutics Reports $36.7 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Unicycive Therapeutics, Inc. Unicycive Therapeutics Reports Improved Liquidity, Reduced Losses, and Advances in Key Drug Candidate

Via official filing (AI summary) | over 1 year ago | 0 comments